Dynavax Technologies (NASDAQ:DVAX) Given “Outperform” Rating at William Blair

William Blair restated their outperform rating on shares of Dynavax Technologies (NASDAQ:DVAX) in a report issued on Friday,RTT News reports.

A number of other analysts have also issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $31.00 target price on shares of Dynavax Technologies in a research report on Friday. The Goldman Sachs Group lowered Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their price objective for the company from $15.00 to $12.00 in a research note on Tuesday, February 11th. Finally, StockNews.com lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th.

Dynavax Technologies Price Performance

Shares of NASDAQ:DVAX opened at $13.33 on Friday. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of 102.55 and a beta of 1.32. The company has a 50 day moving average of $12.81 and a two-hundred day moving average of $11.99. Dynavax Technologies has a 52-week low of $9.74 and a 52-week high of $14.05. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.05. Dynavax Technologies had a net margin of 7.85% and a return on equity of 3.19%. The business had revenue of $72.03 million during the quarter, compared to analyst estimates of $72.70 million. As a group, analysts forecast that Dynavax Technologies will post 0.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dynavax Technologies

Hedge funds and other institutional investors have recently modified their holdings of the stock. US Bancorp DE grew its stake in Dynavax Technologies by 291.4% in the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,034 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in Dynavax Technologies by 96.5% during the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 1,169 shares during the last quarter. Smartleaf Asset Management LLC grew its position in shares of Dynavax Technologies by 463.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 2,034 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Dynavax Technologies in the 4th quarter valued at approximately $35,000. Finally, Capital Performance Advisors LLP bought a new stake in shares of Dynavax Technologies in the 3rd quarter valued at approximately $45,000. Institutional investors own 96.96% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.